GIFLF:OTCMKTS
Grifols SA Class A
11,13 USD
0,00%
(0,00) 1D
15. ruj, 15:11:14 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za GIFLF...
Trž. kap.
6,59 mlr.
Prosj. kol.
543,00
Količina
0,00
52-tjed. najviša
12,90 USD
52-tjed. najniža
10,13 USD
Beta
0,90
Dionice u optjecaju
426,13 mil.
Broj djelatnika
25 tis.
Trž. kap.
6,59 mlr.
Prosj. kol.
543,00
Količina
0,00
52-tjed. najviša
12,90 USD
52-tjed. najniža
10,13 USD
Beta
0,90
Dionice u optjecaju
426,13 mil.
Broj djelatnika
25 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
AD HOC NEWS
·
prije 16 sati
Grifols stock ends the week at EUR 9.88 within a EUR 9.73-9.97 range
AD HOC NEWS
·
prije 1 dan
Grifols stock after-hours at EUR 9.88: plus 0.51 percent
AD HOC NEWS
·
prije 1 dan
Grifols signed a 40 GWh PPA and Grifols stock gained 1.22 percent
AD HOC NEWS
·
prije 1 dan
Grifols stock pre-market at EUR 9.83: unchanged
Profil
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Grifols SA Class A – informacije
Glavni izvršni direktorNacho Abia
Zaposlenici25 tis.
Osnovano18. stu 1940.
Sjedište-
Sektor-
Web-lokacijagrifols.com